ImmunityBio (IBRX) Receivables - Other (2016 - 2025)
ImmunityBio (IBRX) has disclosed Receivables - Other for 11 consecutive years, with $46000.0 as the latest value for Q4 2025.
- On a quarterly basis, Receivables - Other fell 77.0% to $46000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $46000.0, a 77.0% decrease, with the full-year FY2025 number at $46000.0, down 77.0% from a year prior.
- Receivables - Other was $46000.0 for Q4 2025 at ImmunityBio, down from $1.7 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $3.9 million in Q1 2022 to a low of $46000.0 in Q4 2025.
- A 5-year average of $1.3 million and a median of $1.5 million in 2022 define the central range for Receivables - Other.
- Peak YoY movement for Receivables - Other: surged 1711.5% in 2021, then plummeted 93.48% in 2025.
- ImmunityBio's Receivables - Other stood at $1.3 million in 2021, then rose by 11.63% to $1.5 million in 2022, then soared by 35.69% to $2.0 million in 2023, then crashed by 90.09% to $200000.0 in 2024, then tumbled by 77.0% to $46000.0 in 2025.
- Per Business Quant, the three most recent readings for IBRX's Receivables - Other are $46000.0 (Q4 2025), $1.7 million (Q3 2025), and $67000.0 (Q2 2025).